TARS News and Press, Tarsus Pharmaceuticals Inc. From 12/04/23

2023-12-04 12:09:00 ET Summary TARS has launched a new drug, Xdemvy, for the treatment of Demodex blepharitis, with net product sales of $1.7M in the first five weeks following launch. TARS has readouts from three clinical trials due in the next four months, with one due in Q4'23....

2023-11-20 14:47:32 ET More on Tarsus Pharmaceuticals Tarsus Pharmaceuticals, Inc. (TARS) Q3 2023 Earnings Call Transcript Xdemvy: Tarsus' Leading Asset In A Multi-Billion Market Landscape Tarsus Pharmaceuticals, Inc. - Barking Up The Wrong Tree Tarsus Pharma...

2023-11-10 18:59:09 ET Tarsus Pharmaceuticals, Inc. (TARS) Q3 2023 Results Conference Call November 9, 2023 4:30 PM ET Company Participants David Nakasone - Head, IR Bobak Azamian - Chairman, CEO Aziz Mottiwala - CCO Jeff Farrow - CFO, CSO Conference Ca...

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 2.73% on the day to $14.13. Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development...

2023-11-09 17:08:17 ET More on Tarsus Pharmaceuticals Xdemvy: Tarsus' Leading Asset In A Multi-Billion Market Landscape Tarsus Pharmaceuticals, Inc. - Barking Up The Wrong Tree Tarsus Pharmaceuticals: Worthy Of A Small Bet Tarsus Pharmaceuticals' President &a...

2023-11-09 16:34:52 ET More on Tarsus Pharmaceuticals Xdemvy: Tarsus' Leading Asset In A Multi-Billion Market Landscape Tarsus Pharmaceuticals, Inc. - Barking Up The Wrong Tree Tarsus Pharmaceuticals: Worthy Of A Small Bet Tarsus Pharmaceuticals' President &a...

Launched XDEMVY ® (lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis Achieved $1.7 million in net product sales with more than 1,700 dispensed bottles Strengthened balance sheet with an approximately $100 million public equit...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

Tarsus Pharmaceuticals Inc. (TARS) is expected to report $-1.4 for Q3 2023

2023-11-07 07:02:08 ET Summary Demodex Blepharitis (DB), Meibomian Gland Dysfunction (MGD), Dry Eye, Rosacea, and Lyme Disease are common conditions that can be treated with XDEMVY™. XDEMVY™ (lotilaner ophthalmic solution 0.25%) is the first FDA-approved treatment fo...